Becton, Dickinson and Company (BDX) |
| 176.48 -0.18 (-0.1%) 02-27 16:00 |
| Open: | 175.32 |
| High: | 178.01 |
| Low: | 174.03 |
| Volume: | 2,414,197 |
| Market Cap: | 63,938(M) |
| PE Ratio: | 28.84 |
| Exchange: | New York Stock Exchange |
| Industry: | Medical - Instruments & Supplies |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 218.82 |
| Resistance 1: | 187.35 |
| Pivot price: | 177.53 |
| Support 1: | 166.61 |
| Support 2: | 153.80 |
| 52w High: | 187.35 |
| 52w Low: | 127.58648 |
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
| EPS | 6.120 |
| Book Value | 88.790 |
| PEG Ratio | 0.00 |
| Gross Profit | 36.067 |
| Profit Margin (%) | 8.01 |
| Operating Margin (%) | 13.35 |
| Return on Assets (ttm) | 4.1 |
| Return on Equity (ttm) | 7.0 |
Fri, 27 Feb 2026
Becton, Dickinson and Company (NYSE:BDX) EVP Sells $13,638.00 in Stock - MarketBeat
Fri, 27 Feb 2026
Becton, Dickinson and Company (NYSE:BDX) Short Interest Update - MarketBeat
Fri, 27 Feb 2026
Becton, Dickinson and Company $BDX Stock Holdings Decreased by TD Asset Management Inc - MarketBeat
Wed, 25 Feb 2026
Becton, Dickinson and Company (BDX) Announces Early Tender Resul - GuruFocus
Wed, 25 Feb 2026
Becton, Dickinson and Company Announces Pricing of the Tender Offers and Amounts Accepted for Purchase - Becton Dickinson
Tue, 24 Feb 2026
What Makes Becton Dickinson (BDX) a Good Long-Term Investment? - MSN
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |